Adding bevacizumab to neoadjuvant chemotherapy did not improve complete macroscopic response rate or progression-free survival in women with ovarian cancer.
Platinum-sensitive ovarian cancer patients with a positive predictive AGO score who undergo a secondary debulking surgery after relapse on platinum chemotherapy experience longer progression-free survival.
A phase I study combining the PD-L1 inhibitor durvalumab with either olaparib or cediranib found that the combinations are reasonably well tolerated and active in recurrent women’s cancers.
Patients with ovarian cancer who express the NY-ESO-1 testis antigen have significantly shorter overall survival than those who do not, according to a new study. These patients may benefit from immunotherapy agents.
New research suggests that hypertension and diabetes and the use of medications to treat these conditions may influence the survival of ovarian cancer patients.
PARP inhibitors are an active, novel, and exciting class of anticancer agents. They have shown clear patient benefit in gBRCA, HR-deficient, and other ovarian cancers.
The use of cediranib as concurrent treatment with chemotherapy and as maintenance therapy in relapsed ovarian cancer was not associated with declines in quality of life.
The FDA announced the approval of niraparib, an oral PARP inhibitor, for the treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
A novel compound known as PM01183 showed promising activity in a two-stage phase II trial of women with platinum-resistant/refractory ovarian cancer.
The addition of the immune therapy motolimod to pegylated liposomal doxorubicin failed to improve overall survival among women with recurrent epithelial ovarian carcinoma in a randomized phase II trial.